The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Oslei Paes De Almeida - One of the best experts on this subject based on the ideXlab platform.
-
immunohistochemical expression of podoplanin d2 40 lymphangiogenesis and neoangiogenesis in tooth germ Ameloblastomas and ameloblastic carcinomas
Journal of Oral Pathology & Medicine, 2017Co-Authors: Celeste Sanchezromero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De AlmeidaAbstract:Background Ameloblastoma is a benign but locally aggressive odontogenic tumor, while ameloblastic carcinoma is its malignant counterpart. Angiogenesis and lymphangiogenesis in malignancies have been correlated with higher aggressiveness and poor prognosis, as well as greater expression of podoplanin by tumoral cells. Methods Immunohistochemical expression of podoplanin, CD34, and CD105 (endoglin) was evaluated in 53 Ameloblastomas and three ameloblastic carcinomas; additionally, immunohistochemistry for podoplanin was also performed in 10 tooth germs. Microvessel density of blood and lymphatic vessels was calculated and compared between Ameloblastomas and ameloblastic carcinomas. Immunoexpression of podoplanin by ameloblastic cells was evaluated in tooth germs, Ameloblastomas, and ameloblastic carcinomas. Results Podoplanin was similarly expressed by odontogenic epithelial cells of tooth germs and Ameloblastomas, while its expression was lower in ameloblastic carcinomas. There was no difference in microvessel density assessed by CD34 between Ameloblastomas and ameloblastic carcinomas; nevertheless, the latter presented higher amounts of lymphatic and new formed blood vessels. Conclusions Results suggest that podoplanin does not seem to be involved in invasion mechanisms of ameloblastic carcinomas, as its expression was decreased in the malignant tumoral cells. On the other hand, the increased lymphatic microvessel density and neoangiogenesis found in ameloblastic carcinomas could be related to its aggressiveness and potential for metastasis.
-
comparative expression of syndecan 1 and ki 67 in peripheral and desmoplastic Ameloblastomas and ameloblastic carcinoma
Pathology International, 2009Co-Authors: J E Farfanmorales, Nelly Molinafrechero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, Pablo DamianmatsumuraAbstract:The aims of the present study were to examine whether the pattern of syndecan-1 expression correlates with cellular proliferation index in desmoplastic Ameloblastomas (DA), peripheral Ameloblastomas (PA) and ameloblastic carcinomas (AC), and to compare with that previously reported for solid (SA) and unicystic (UA) variants of Ameloblastoma. Immunohistochemistry was performed for syndecan-1 and Ki-67 in seven Ameloblastomas (four DA and three PA) and three AC. Expression of syndecan-1 was related to the histological subtype of tumors and, in the case of malignancy, to lower expression levels observed in AC (22.5%) than in PA (47.5%) or DA (77.5%) (P < 0.05). Syndecan-1 expression correlated inversely with Ki-67 proliferative index: the expression was lower in both types of Ameloblastomas (1.5% in DA and 6.4% in PA) than in AC (41.2%; P < 0.05). The present results suggest that the decrease in syndecan-1 expression and increase in the Ki-67 index observed in AC is in accordance with its higher aggressiveness as compared to the rare DA and PA. Interestingly, DA had a lower proliferation index as well as the highest levels of syndecan-1 expression. These data suggest that DA differ from the other types of intraosseous Ameloblastomas but more studies are necessary to better understand the role of this protein as a marker in the biological behavior of the epithelial odontogenic neoplasms.
-
syndecan 1 cd138 and ki 67 expression in different subtypes of Ameloblastomas
Oral Oncology, 2008Co-Authors: Ronell Bolognamolina, J E Farfanmorales, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, F Garciavazquez, Maria Esther Irigoyencamacho, Pablo DamianmatsumuraAbstract:Summary Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression. Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. The aims of this study were to examine the pattern of syndecan-1 expression, to evaluate the proliferating activity in a large series of solid/multicystic (SA) and unicystic Ameloblastomas (UA), and to study its possible correlation to their biological behavior. Immunohistochemical studies were performed for syndecan-1 (clone MI15) and Ki-67 (clone MIB-1) in 120 Ameloblastomas (75 SA and 45 UA). The salient finding was that expression of syndecan-1 was related to the histological subtype of tumors, as there was a lower expression in SA (40.2%) as compared to UA (49.7%) (p
Ronell Bolognamolina - One of the best experts on this subject based on the ideXlab platform.
-
immunohistochemical expression of podoplanin d2 40 lymphangiogenesis and neoangiogenesis in tooth germ Ameloblastomas and ameloblastic carcinomas
Journal of Oral Pathology & Medicine, 2017Co-Authors: Celeste Sanchezromero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De AlmeidaAbstract:Background Ameloblastoma is a benign but locally aggressive odontogenic tumor, while ameloblastic carcinoma is its malignant counterpart. Angiogenesis and lymphangiogenesis in malignancies have been correlated with higher aggressiveness and poor prognosis, as well as greater expression of podoplanin by tumoral cells. Methods Immunohistochemical expression of podoplanin, CD34, and CD105 (endoglin) was evaluated in 53 Ameloblastomas and three ameloblastic carcinomas; additionally, immunohistochemistry for podoplanin was also performed in 10 tooth germs. Microvessel density of blood and lymphatic vessels was calculated and compared between Ameloblastomas and ameloblastic carcinomas. Immunoexpression of podoplanin by ameloblastic cells was evaluated in tooth germs, Ameloblastomas, and ameloblastic carcinomas. Results Podoplanin was similarly expressed by odontogenic epithelial cells of tooth germs and Ameloblastomas, while its expression was lower in ameloblastic carcinomas. There was no difference in microvessel density assessed by CD34 between Ameloblastomas and ameloblastic carcinomas; nevertheless, the latter presented higher amounts of lymphatic and new formed blood vessels. Conclusions Results suggest that podoplanin does not seem to be involved in invasion mechanisms of ameloblastic carcinomas, as its expression was decreased in the malignant tumoral cells. On the other hand, the increased lymphatic microvessel density and neoangiogenesis found in ameloblastic carcinomas could be related to its aggressiveness and potential for metastasis.
-
orosomucoid 1 expression in Ameloblastoma variants
International Journal of Molecular and Cellular Medicine, 2016Co-Authors: Alejandro Garciamunoz, Rodrigo Liceagareyes, J E Farfanmorales, Saray Arandaromo, Mario A Rodriguez, Nelly Molinafrechero, Ronell Bolognamolina, Rogelio GonzalezgonzalezAbstract:Odontogenic tumors constitute a group of heterogeneous lesions of benign and malignant neoplasms with variable aggressiveness. Ameloblastomas are a group of benign but locally invasive neoplasms that occur in the jaws and are derived from epithelial elements of the tooth-forming apparatus. We previously described orosomucoid-1 protein expression in odontogenic myxomas. However, whether orosomucoid-1 is expressed in other odontogenic tumors remains unknown. Since orosomucoid-1 belongs to a group of acute-phase proteins and has many functions in health and disease, we identified and analyzed orosomucoid-1 expression in Ameloblastoma variants and ameloblastic carcinoma using western blot and immunohistochemical techniques. Thirty cases of Ameloblastoma were analyzed for orsomucoid-1; five specimens were fresh for western blot study (four benign Ameloblastomas and one ameloblastic carcinoma), and 25 cases of benign Ameloblastoma for immunohistochemical assays. Orosomucoid-1 was widely expressed in each tumor variant analyzed in this study, and differential orosomucoid-1 expression was observed between benign and malignant tumor. Orosomucoid-1 may play an important role in the behavior of Ameloblastomas and influence the biology and development of the variants of this tumor.
-
comparative expression of syndecan 1 and ki 67 in peripheral and desmoplastic Ameloblastomas and ameloblastic carcinoma
Pathology International, 2009Co-Authors: J E Farfanmorales, Nelly Molinafrechero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, Pablo DamianmatsumuraAbstract:The aims of the present study were to examine whether the pattern of syndecan-1 expression correlates with cellular proliferation index in desmoplastic Ameloblastomas (DA), peripheral Ameloblastomas (PA) and ameloblastic carcinomas (AC), and to compare with that previously reported for solid (SA) and unicystic (UA) variants of Ameloblastoma. Immunohistochemistry was performed for syndecan-1 and Ki-67 in seven Ameloblastomas (four DA and three PA) and three AC. Expression of syndecan-1 was related to the histological subtype of tumors and, in the case of malignancy, to lower expression levels observed in AC (22.5%) than in PA (47.5%) or DA (77.5%) (P < 0.05). Syndecan-1 expression correlated inversely with Ki-67 proliferative index: the expression was lower in both types of Ameloblastomas (1.5% in DA and 6.4% in PA) than in AC (41.2%; P < 0.05). The present results suggest that the decrease in syndecan-1 expression and increase in the Ki-67 index observed in AC is in accordance with its higher aggressiveness as compared to the rare DA and PA. Interestingly, DA had a lower proliferation index as well as the highest levels of syndecan-1 expression. These data suggest that DA differ from the other types of intraosseous Ameloblastomas but more studies are necessary to better understand the role of this protein as a marker in the biological behavior of the epithelial odontogenic neoplasms.
-
syndecan 1 cd138 and ki 67 expression in different subtypes of Ameloblastomas
Oral Oncology, 2008Co-Authors: Ronell Bolognamolina, J E Farfanmorales, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, F Garciavazquez, Maria Esther Irigoyencamacho, Pablo DamianmatsumuraAbstract:Summary Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression. Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. The aims of this study were to examine the pattern of syndecan-1 expression, to evaluate the proliferating activity in a large series of solid/multicystic (SA) and unicystic Ameloblastomas (UA), and to study its possible correlation to their biological behavior. Immunohistochemical studies were performed for syndecan-1 (clone MI15) and Ki-67 (clone MIB-1) in 120 Ameloblastomas (75 SA and 45 UA). The salient finding was that expression of syndecan-1 was related to the histological subtype of tumors, as there was a lower expression in SA (40.2%) as compared to UA (49.7%) (p
Adalberto Mosquedataylor - One of the best experts on this subject based on the ideXlab platform.
-
immunohistochemical expression of podoplanin d2 40 lymphangiogenesis and neoangiogenesis in tooth germ Ameloblastomas and ameloblastic carcinomas
Journal of Oral Pathology & Medicine, 2017Co-Authors: Celeste Sanchezromero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De AlmeidaAbstract:Background Ameloblastoma is a benign but locally aggressive odontogenic tumor, while ameloblastic carcinoma is its malignant counterpart. Angiogenesis and lymphangiogenesis in malignancies have been correlated with higher aggressiveness and poor prognosis, as well as greater expression of podoplanin by tumoral cells. Methods Immunohistochemical expression of podoplanin, CD34, and CD105 (endoglin) was evaluated in 53 Ameloblastomas and three ameloblastic carcinomas; additionally, immunohistochemistry for podoplanin was also performed in 10 tooth germs. Microvessel density of blood and lymphatic vessels was calculated and compared between Ameloblastomas and ameloblastic carcinomas. Immunoexpression of podoplanin by ameloblastic cells was evaluated in tooth germs, Ameloblastomas, and ameloblastic carcinomas. Results Podoplanin was similarly expressed by odontogenic epithelial cells of tooth germs and Ameloblastomas, while its expression was lower in ameloblastic carcinomas. There was no difference in microvessel density assessed by CD34 between Ameloblastomas and ameloblastic carcinomas; nevertheless, the latter presented higher amounts of lymphatic and new formed blood vessels. Conclusions Results suggest that podoplanin does not seem to be involved in invasion mechanisms of ameloblastic carcinomas, as its expression was decreased in the malignant tumoral cells. On the other hand, the increased lymphatic microvessel density and neoangiogenesis found in ameloblastic carcinomas could be related to its aggressiveness and potential for metastasis.
-
comparative expression of syndecan 1 and ki 67 in peripheral and desmoplastic Ameloblastomas and ameloblastic carcinoma
Pathology International, 2009Co-Authors: J E Farfanmorales, Nelly Molinafrechero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, Pablo DamianmatsumuraAbstract:The aims of the present study were to examine whether the pattern of syndecan-1 expression correlates with cellular proliferation index in desmoplastic Ameloblastomas (DA), peripheral Ameloblastomas (PA) and ameloblastic carcinomas (AC), and to compare with that previously reported for solid (SA) and unicystic (UA) variants of Ameloblastoma. Immunohistochemistry was performed for syndecan-1 and Ki-67 in seven Ameloblastomas (four DA and three PA) and three AC. Expression of syndecan-1 was related to the histological subtype of tumors and, in the case of malignancy, to lower expression levels observed in AC (22.5%) than in PA (47.5%) or DA (77.5%) (P < 0.05). Syndecan-1 expression correlated inversely with Ki-67 proliferative index: the expression was lower in both types of Ameloblastomas (1.5% in DA and 6.4% in PA) than in AC (41.2%; P < 0.05). The present results suggest that the decrease in syndecan-1 expression and increase in the Ki-67 index observed in AC is in accordance with its higher aggressiveness as compared to the rare DA and PA. Interestingly, DA had a lower proliferation index as well as the highest levels of syndecan-1 expression. These data suggest that DA differ from the other types of intraosseous Ameloblastomas but more studies are necessary to better understand the role of this protein as a marker in the biological behavior of the epithelial odontogenic neoplasms.
-
syndecan 1 cd138 and ki 67 expression in different subtypes of Ameloblastomas
Oral Oncology, 2008Co-Authors: Ronell Bolognamolina, J E Farfanmorales, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, F Garciavazquez, Maria Esther Irigoyencamacho, Pablo DamianmatsumuraAbstract:Summary Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression. Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. The aims of this study were to examine the pattern of syndecan-1 expression, to evaluate the proliferating activity in a large series of solid/multicystic (SA) and unicystic Ameloblastomas (UA), and to study its possible correlation to their biological behavior. Immunohistochemical studies were performed for syndecan-1 (clone MI15) and Ki-67 (clone MIB-1) in 120 Ameloblastomas (75 SA and 45 UA). The salient finding was that expression of syndecan-1 was related to the histological subtype of tumors, as there was a lower expression in SA (40.2%) as compared to UA (49.7%) (p
Pablo Damianmatsumura - One of the best experts on this subject based on the ideXlab platform.
-
comparative expression of syndecan 1 and ki 67 in peripheral and desmoplastic Ameloblastomas and ameloblastic carcinoma
Pathology International, 2009Co-Authors: J E Farfanmorales, Nelly Molinafrechero, Ronell Bolognamolina, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, Pablo DamianmatsumuraAbstract:The aims of the present study were to examine whether the pattern of syndecan-1 expression correlates with cellular proliferation index in desmoplastic Ameloblastomas (DA), peripheral Ameloblastomas (PA) and ameloblastic carcinomas (AC), and to compare with that previously reported for solid (SA) and unicystic (UA) variants of Ameloblastoma. Immunohistochemistry was performed for syndecan-1 and Ki-67 in seven Ameloblastomas (four DA and three PA) and three AC. Expression of syndecan-1 was related to the histological subtype of tumors and, in the case of malignancy, to lower expression levels observed in AC (22.5%) than in PA (47.5%) or DA (77.5%) (P < 0.05). Syndecan-1 expression correlated inversely with Ki-67 proliferative index: the expression was lower in both types of Ameloblastomas (1.5% in DA and 6.4% in PA) than in AC (41.2%; P < 0.05). The present results suggest that the decrease in syndecan-1 expression and increase in the Ki-67 index observed in AC is in accordance with its higher aggressiveness as compared to the rare DA and PA. Interestingly, DA had a lower proliferation index as well as the highest levels of syndecan-1 expression. These data suggest that DA differ from the other types of intraosseous Ameloblastomas but more studies are necessary to better understand the role of this protein as a marker in the biological behavior of the epithelial odontogenic neoplasms.
-
syndecan 1 cd138 and ki 67 expression in different subtypes of Ameloblastomas
Oral Oncology, 2008Co-Authors: Ronell Bolognamolina, J E Farfanmorales, Adalberto Mosquedataylor, Oslei Paes De Almeida, Eduardo Lopezcorella, Daniel Carrascodaza, F Garciavazquez, Maria Esther Irigoyencamacho, Pablo DamianmatsumuraAbstract:Summary Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression. Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. The aims of this study were to examine the pattern of syndecan-1 expression, to evaluate the proliferating activity in a large series of solid/multicystic (SA) and unicystic Ameloblastomas (UA), and to study its possible correlation to their biological behavior. Immunohistochemical studies were performed for syndecan-1 (clone MI15) and Ki-67 (clone MIB-1) in 120 Ameloblastomas (75 SA and 45 UA). The salient finding was that expression of syndecan-1 was related to the histological subtype of tumors, as there was a lower expression in SA (40.2%) as compared to UA (49.7%) (p
Seong-doo Hong - One of the best experts on this subject based on the ideXlab platform.
-
high prevalence of braf v600e mutations in korean patients with Ameloblastoma clinicopathological significance and correlation with epithelial mesenchymal transition
Journal of Oral Pathology & Medicine, 2019Co-Authors: Sungdae Cho, Hye-jung Yoon, Jae-il Lee, Sunha Ahn, Seong-doo HongAbstract:Background BRAF V600E mutations are activating mutations that have recently been detected in Ameloblastoma. However, their prevalence has not been reported in East Asian patients with Ameloblastoma and their clinicopathological significance remains unclear. In this study, we examined the prevalence and clinicopathological significance of BRAF V600E mutations in Korean patients with Ameloblastoma. In addition, we investigated the relationship between BRAF V600E mutations and epithelial-mesenchymal transition, which has not been studied in Ameloblastoma. Methods Thirty Ameloblastoma tissue samples were collected, and DNA isolation, polymerase chain reaction, and Sanger sequencing were performed to detect BRAF V600E mutations. Immunohistochemistry was carried out using antibodies against two epithelial-mesenchymal transition-inducing transcription factors, Twist and Snail. Associations of BRAF V600E mutations with clinicopathological factors and expression of Twist and Snail were statistically analyzed. Results We found a high frequency (90.0%) of BRAF V600E mutations, and mutation status was not associated with clinicopathological factors including age, tumor location, and recurrence. Positive expression of Twist and Snail was observed in 33.3% and 56.7% of cases, respectively, and associated with recurrence (P = 0.020 and 0.010, respectively). There was no correlation between BRAF V600E mutation status and expression of Twist and Snail (P = 1.000, for both). Conclusions A higher prevalence of BRAF V600E mutations was identified in Korean patients with Ameloblastoma compared with previous studies, which indicates that BRAF-targeted therapies can be widely used for refractory Ameloblastomas. Furthermore, our findings suggest that BRAF V600E mutations and epithelial-mesenchymal transition may act independently in the development of Ameloblastoma.
-
Comparative immunohistochemical study of Ameloblastoma and ameloblastic carcinoma.
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2011Co-Authors: Hye-jung Yoon, Wui-jung Shin, Young-ah Cho, Jae-il Lee, Sam-pyo Hong, Seong-doo HongAbstract:Objective Ameloblastic carcinoma combines the histologic features of Ameloblastoma with cytologic atypia, regardless of whether it has metastasized. Because of its rarity, there are few immunoprofile studies of ameloblastic carcinoma and few comparative studies of ameloblastic carcinoma and Ameloblastoma. In this study, we compared the expression levels of cytokeratins (CKs), matrix metalloproteinases (MMPs), and Ki-67 between Ameloblastoma and ameloblastic carcinoma, and assessed the usefulness of these markers for differentiating the tumors. Study design We assessed CK7, CK14, CK18, CK19, MMP-2, MMP-9, and Ki-67 expression by immunohistochemistry in 10 cases of Ameloblastoma and 7 cases of ameloblastic carcinoma and then compared expression patterns between the 2 groups. Results Immunostaining for CK14 and CK19 was diffuse and strongly positive in both tumor types, but staining for CK7 was focally positive in only 1 case of Ameloblastoma and absent in all cases of ameloblastic carcinoma. However, there was a significant difference in CK18 expression between the 2 tumors ( P = .000). Whereas 80% of Ameloblastomas showed negative reactivity for CK18, most cases of ameloblastic carcinomas showed a moderate to strong intensity of immunostaining for CK18. Regarding the expression of MMPs, there were significant differences in parenchymal MMP-2 and stromal MMP-9 expression between the 2 tumors. Compared to Ameloblastoma, ameloblastic carcinoma showed significantly strong expression of MMP-2 in parenchymal cells ( P = .001) and MMP-9 in stromal cells ( P = .013). However, there were no differences in MMP-2 expression of stromal cells and MMP-9 expression of parenchymal cells between Ameloblastoma and ameloblastic carcinoma. The mean Ki-67 labeling index (LI) of ameloblastic carcinomas was 17.21%, which was significantly higher than that of Ameloblastomas (3.57%; P = .002). Conclusions The significant expression of CK18, parenchymal MMP-2, stromal MMP-9, and Ki-67 could provide useful markers for differentiating ameloblastic carcinoma from Ameloblastoma.